Published in N Engl J Med on November 04, 2007
Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study (GeCCO) | NCT00995514
The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation | NCT01099566
Association Between Genetic Variant Scores and P2Y12 Inhibitor Effects (CARES1) | NCT04580602
Role of Immune Responses After Acute Myocardial Infarction (BATTLE-AMI) | NCT02428374
P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI (P2BiTO) | NCT01967615
Plavix, Prasugrel and Drug Eluting Stents Pilot Trial (PPD) | NCT01103843
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther (2012) 4.05
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53
Triggers, targets and treatments for thrombosis. Nature (2008) 3.51
Effect of smoking on comparative efficacy of antiplatelet agents: systematic review, meta-analysis, and indirect comparison. BMJ (2013) 3.43
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study. Ann Intern Med (2010) 2.90
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J (2013) 2.81
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther (2013) 2.73
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet (2010) 2.72
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ (2011) 2.68
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy (2012) 2.49
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J (2011) 2.40
Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ (2014) 2.21
Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med (2011) 1.92
Antiplatelet effects of dietary nitrate in healthy volunteers: involvement of cGMP and influence of sex. Free Radic Biol Med (2013) 1.78
Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J (2010) 1.74
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther (2009) 1.73
Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov (2010) 1.66
Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc (2010) 1.58
Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events. Eur Heart J (2009) 1.53
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J (2014) 1.51
Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J (2015) 1.48
Electronic health record design and implementation for pharmacogenomics: a local perspective. Genet Med (2013) 1.48
Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. J Am Coll Cardiol (2013) 1.47
Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. Blood Transfus (2015) 1.46
Intensifying platelet inhibition--navigating between Scylla and Charybdis. N Engl J Med (2007) 1.46
Transcarpal cardiac catheterization. Dtsch Arztebl Int (2009) 1.43
Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk. Sci Transl Med (2014) 1.42
Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J (2015) 1.41
"Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States. Catheter Cardiovasc Interv (2015) 1.39
Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Arterioscler Thromb Vasc Biol (2016) 1.39
Acute coronary syndromes: diagnosis and management, part I. Mayo Clin Proc (2009) 1.38
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J (2010) 1.34
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. J Neurointerv Surg (2012) 1.28
Management of peripheral arterial interventions with mono or dual antiplatelet therapy--the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol (2012) 1.25
Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc (2015) 1.24
Recent advances in antithrombotic therapy after acute coronary syndrome. CMAJ (2013) 1.23
Management of cardiovascular disease in patients with kidney disease. Nat Rev Cardiol (2013) 1.23
An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf (2011) 1.14
Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol (2010) 1.13
Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol (2010) 1.13
Outcome selection and role of patient reported outcomes in contemporary cardiovascular trials: systematic review. BMJ (2010) 1.13
Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol (2011) 1.09
New antiplatelet agents for cardiovascular disease. CMAJ (2013) 1.09
Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Nat Rev Drug Discov (2010) 1.08
Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. PLoS One (2013) 1.07
Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J (2009) 1.07
The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors. Dtsch Arztebl Int (2013) 1.07
Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol (2010) 1.06
Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis. J Clin Invest (2014) 1.06
Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. Proc Natl Acad Sci U S A (2010) 1.05
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. Br J Pharmacol (2009) 1.05
Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proc Natl Acad Sci U S A (2012) 1.05
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2014) 1.05
Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care (2009) 1.03
Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. Blood (2014) 1.02
Adoption of prasugrel into routine practice: rationale and design of the Rijnmond Collective Cardiology Research (CCR) study in percutaneous coronary intervention for acute coronary syndromes. Neth Heart J (2014) 1.00
P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells. Purinergic Signal (2012) 1.00
Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol (2011) 0.99
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J (2008) 0.99
Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions. Neth Heart J (2015) 0.98
P2 receptors and platelet function. Purinergic Signal (2011) 0.98
Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users : A position statement on the use of bioresorbable vascular scaffolds in the Netherlands. Neth Heart J (2015) 0.98
Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol (2009) 0.97
P2Y12 platelet inhibition in clinical practice. J Thromb Thrombolysis (2012) 0.97
The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. Eur J Clin Pharmacol (2009) 0.97
Myocardial infarction in the elderly. Aging Dis (2010) 0.96
Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. Circulation (2011) 0.96
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J (2013) 0.96
Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis (2011) 0.96
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol (2012) 0.95
Nonadherence to treatment protocol in published randomised controlled trials: a review. Trials (2012) 0.94
Dual antiplatelet therapy over 6 months increases the risk of bleeding after biodegradable polymer-coated sirolimus eluting stents implantation: insights from the CREATE study. J Interv Cardiol (2014) 0.94
Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation (2012) 0.94
Discovery of 1,3-Diaminobenzenes as Selective Inhibitors of Platelet Activation at the PAR1 Receptor. ACS Med Chem Lett (2012) 0.94
Temporal trends in gastrointestinal bleeding associated with percutaneous coronary intervention: analysis of the 1998-2006 Nationwide Inpatient Sample (NIS) database. Am Heart J (2011) 0.94
Percutaneous coronary intervention in the elderly. Nat Rev Cardiol (2010) 0.93
Anticoagulation in heart failure: current status and future direction. Heart Fail Rev (2013) 0.93
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med (2011) 0.93
Combination of Chinese Herbal Medicines and Conventional Treatment versus Conventional Treatment Alone in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention (5C Trial): An Open-Label Randomized Controlled, Multicenter Study. Evid Based Complement Alternat Med (2013) 0.92
Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol (2011) 0.92
Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor. Vasc Health Risk Manag (2010) 0.92
Novel agents for anti-platelet therapy. J Hematol Oncol (2011) 0.92
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets (2013) 0.91
High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. Cardiovasc Diagn Ther (2013) 0.91
Prevention and management of TURP-related hemorrhage. Nat Rev Urol (2011) 0.90
Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future. Br J Pharmacol (2014) 0.90
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag (2009) 0.90
Prasugrel. Nat Rev Drug Discov (2009) 0.90
Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial. Heart Vessels (2012) 0.90
Bariatric surgery: a systematic review and meta-analysis. JAMA (2004) 23.34
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99
Universal definition of myocardial infarction. Circulation (2007) 11.69
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med (2010) 7.39
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J (2005) 6.86
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med (2007) 6.79
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet (2008) 6.41
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation (2004) 6.34
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J (2006) 5.79
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med (2010) 5.43
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28
Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med (2009) 5.19
New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet (2009) 5.12
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72
Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2003) 4.70
A tale of coronary artery disease and myocardial infarction. N Engl J Med (2012) 4.53
Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol (2008) 4.51
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49